- Starpharma (SPL) signs a deal with ADMENTA Italia Group for its VIRALEZE treatment to be distributed in Italy
- Under the agreement, Starpharma will supply the VIRALEZE, with ADMENTA responsible for distribution, sales, and marketing of the product in Italy
- The nasal spray is expected to be available to Italian consumers in stores and via LloydsFarmacia’s online platform this quarter
- The antiviral nasal spray is now registered in Europe and India and is available in certain markets online
- Starpharma’s shares are up 1.67 per cent to trade at $1.22
Starpharma (SPL) has signed a deal for its VIRALEZE treatment to be distributed in Italy.
VIRALEZE is an antiviral nasal spray which provides a physical barrier to trap and inactivate viruses, including SARS-CoV-2, which has been proven to have a greater than 99.9 per cent inactivation of the Delta variant of COVID-19.
The sales and distribution agreement for the antiviral nasal spray is with ADMENTA Italia Group, a pharmaceutical retail and wholesale distribution company, considered the third largest in Europe.
ADMENTA operates over 260 pharmacies under its LloydsFarmacia brand. ADMENTA employs around 1400 people in Italy across both wholesale and retail, supplying over 2500 pharmacies, parapharmacies, drug stores and hospitals.
Under the agreement, Starpharma will supply VIRALEZE, with ADMENTA responsible for distribution, sales, and marketing of the product in Italy.
Starpharma CEO, Dr Jackie Fairley, was pleased to have signed this deal.
“We are very pleased to have partnered with ADMENTA in Italy and we look forward to having VIRALEZE available soon to Italian consumers, through pharmacies as well as through the leading LloydsFarmacia online platform.”
VIRALEZE is expected to be available to Italian consumers in stores and via LloydsFarmacia’s online platform this quarter.
The antiviral nasal spray is now registered in Europe and India and is available in certain markets online.
Starpharma’s shares were up 1.67 per cent to trade at $1.22 at 10:42 am AEDT.